报价延迟最少15分钟:2026/01/08 17:08 EST
盘后时段
|
||||
|
5.51 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.51
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-9.37/0.64
|
|
企业价值
117.41M
|
| 资产负债 |
|
每股账面净值
7.50
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
19.89M
|
|
每股收益
0.13
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA. |
